🇺🇸 FDA
Patent

US 8796428

Erk1/2 posphorylation site specific antibody

granted A61PA61P35/04A61P9/00

Quick answer

US patent 8796428 (Erk1/2 posphorylation site specific antibody) held by Julius-Maximilians-Universitat Wurzburg expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Julius-Maximilians-Universitat Wurzburg
Grant date
Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P35/04, A61P9/00